Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Shionogi & Co ( (JP:4507) ) is now available.
GSK, Pfizer and Shionogi have completed a reshaping of their stakes in HIV specialist ViiV Healthcare, with Pfizer exiting its 11.7% economic interest and Shionogi increasing its holding to 21.7%, while GSK retains a 78.3% majority stake. ViiV Healthcare issued new shares to Shionogi for $2.125 billion, cancelling Pfizer’s interest, with Pfizer receiving $1.875 billion and GSK collecting a $250 million special dividend, simplifying the ownership structure and extinguishing GSK’s Pfizer-related put option liability.
The transaction strengthens Shionogi’s strategic exposure to the global HIV market through ViiV Healthcare and consolidates GSK’s control, potentially aligning decision-making and long-term planning within the joint venture. For GSK, removal of the put option liability cleans up its balance sheet and may reduce future earnings volatility, while Pfizer’s exit signals a redeployment of capital away from the specialist HIV venture toward its other core priorities.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen4051.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company focused on developing and marketing medicines for infectious diseases and central nervous system disorders. The company has a history of discovering novel antibiotics and treatments for HIV and influenza, positioning it as a key player in anti-infective and related therapeutic areas.
Average Trading Volume: 3,049,368
Technical Sentiment Signal: Buy
Current Market Cap: Yen3071.3B
See more data about 4507 stock on TipRanks’ Stock Analysis page.